Amalgamated Bank decreased its stake in Allergan PLC. (NYSE:AGN) by 21.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,627 shares of the company’s stock after selling 6,562 shares during the period. Amalgamated Bank’s holdings in Allergan PLC. were worth $5,884,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. United Capital Financial Advisers LLC increased its stake in shares of Allergan PLC. by 25.8% in the first quarter. United Capital Financial Advisers LLC now owns 8,407 shares of the company’s stock valued at $2,009,000 after buying an additional 1,722 shares during the last quarter. KCG Holdings Inc. bought a new stake in shares of Allergan PLC. during the first quarter valued at approximately $2,371,000. Epoch Investment Partners Inc. increased its stake in shares of Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock valued at $481,045,000 after buying an additional 73,081 shares during the last quarter. King Luther Capital Management Corp increased its stake in shares of Allergan PLC. by 1.4% in the first quarter. King Luther Capital Management Corp now owns 28,659 shares of the company’s stock valued at $6,847,000 after buying an additional 409 shares during the last quarter. Finally, First Heartland Consultants Inc. increased its stake in shares of Allergan PLC. by 28.8% in the first quarter. First Heartland Consultants Inc. now owns 5,368 shares of the company’s stock valued at $1,283,000 after buying an additional 1,200 shares during the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.
Shares of Allergan PLC. (NYSE:AGN) traded down 0.14% on Friday, reaching $224.45. 565,626 shares of the company traded hands. The stock’s 50 day moving average price is $243.88 and its 200-day moving average price is $238.60. The stock has a market capitalization of $75.03 billion, a P/E ratio of 6.84 and a beta of 1.16. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the firm posted $3.35 earnings per share. Equities analysts forecast that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.25%. Allergan PLC.’s dividend payout ratio is currently 9.95%.
A number of analysts have issued reports on the stock. BidaskClub downgraded shares of Allergan PLC. from a “hold” rating to a “sell” rating in a report on Thursday. Argus reissued a “buy” rating and issued a $280.00 price objective on shares of Allergan PLC. in a report on Monday. UBS AG reissued an “outperform” rating and issued a $275.00 price objective on shares of Allergan PLC. in a report on Wednesday, August 9th. Deutsche Bank AG reissued a “buy” rating and issued a $278.00 price objective (up previously from $273.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Finally, Wells Fargo & Company reissued an “outperform” rating and issued a $280.00 price objective (up previously from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $275.49.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.
